TLDRs; Ford shares slip slightly after reports of a potential US EV partnership with Xiaomi were denied. Speculation about Chinese joint ventures raises investorTLDRs; Ford shares slip slightly after reports of a potential US EV partnership with Xiaomi were denied. Speculation about Chinese joint ventures raises investor

Ford (F) Stock; Dips Modestly on EV Collaboration Speculation

2026/02/02 15:40
3 min read

TLDRs;

  • Ford shares slip slightly after reports of a potential US EV partnership with Xiaomi were denied.
  • Speculation about Chinese joint ventures raises investor concerns about tariffs and national security risks.
  • Ford defends use of licensed Chinese tech while navigating political scrutiny over US battery plant plans.
  • Analysts note domestic automakers face pressure to compete against affordable Chinese EVs despite regulatory hurdles.

Ford (NYSE: F) shares experienced a modest decline on Monday after media reports suggested preliminary discussions between the automaker and Chinese tech giant Xiaomi regarding a potential joint venture for electric vehicle production in the United States.

While sources had indicated that talks may have included other Chinese automakers, such as BYD, both Ford and Xiaomi quickly denied any active negotiations.

Investors appeared cautious in response to the news, sending the stock down slightly, reflecting concerns about political and regulatory obstacles. “Any partnership with a Chinese company in the EV sector would naturally draw scrutiny,” said one industry analyst.

National Security and Tariff Considerations

The rumored discussions come at a time when U.S. policymakers have heightened scrutiny of Chinese involvement in American industries. The federal government maintains high tariffs and restrictions on Chinese vehicle imports, with some officials citing national security risks should Chinese automakers operate in the U.S. market.

Ford’s cautious approach underscores the challenges domestic automakers face. Licensing or collaborating with Chinese firms could provide access to competitive technology but may trigger political backlash or threaten eligibility for federal incentives tied to U.S.-made technology.


F Stock Card
Ford Motor Company, F

Ford’s Strategic Balancing Act

The reports also highlight broader tensions surrounding Ford’s ongoing projects. The automaker recently faced political scrutiny over its planned Michigan battery plant, which relies on licensed technology from Contemporary Amperex Technology Co. Limited (CATL).

Proposed legislation would remove federal tax credits from projects that incorporate Chinese technology, potentially affecting the plant’s financial viability.

CEO Jim Farley has defended the strategy, emphasizing that using licensed Chinese intellectual property allows Ford to bring advanced EV technology to the U.S. while building capacity for American workers. “Learning from established technology helps us scale efficiently,” Farley said, reiterating that no formal joint ventures are underway.

Competition Pressures Domestic Automakers

Beyond political concerns, Ford faces mounting competitive pressures. Chinese EV models, such as Xiaomi’s SU7, have gained attention for combining affordability and performance, contrasting with the roughly $50,000 average price of new vehicles in the U.S.

Meanwhile, Ford has announced plans to take a $19.5 billion write-down and drop several EV models, signaling the high costs of catching up in the market.

Analysts note that some domestic automakers may consider licensing or limited joint ventures to compete effectively, despite the regulatory hurdles. Polling shows that 79% of Americans cite national security concerns over Chinese cars, yet more than half would still consider purchasing them. This tension reflects the difficult balance between consumer demand, technology access, and national security.

Looking Ahead

Ford’s stock movement Monday may be modest, but the underlying dynamics highlight the complex landscape for U.S. automakers. Investors will be watching closely as political, technological, and competitive pressures converge, shaping how American companies navigate partnerships, technology licensing, and EV production strategy.

The post Ford (F) Stock; Dips Modestly on EV Collaboration Speculation appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26